Garodia Chemicals Withdraws Record Date for Share Restructuring

Introduction

Garodia Chemicals Limited has unexpectedly withdrawn the record date for its planned share capital reduction and subdivision, creating uncertainty around its corporate restructuring process. The company formally communicated this decision to the BSE on April 2, 2026, retracting the previously announced date of March 25, 2026. This move puts a pause on a key component of the company's National Company Law Tribunal (NCLT) approved Base Resolution Plan (BRP), which was designed to overhaul its capital structure and aid in its financial turnaround.

The Sudden Reversal

In a formal intimation to the stock exchange, Managing Director Ravindra Subhash Salunkhe confirmed the withdrawal. The communication, filed in compliance with SEBI's Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015, stated that the record date of March 25, 2026, stands "completely withdrawn." The company's filing did not provide any specific reasons for this abrupt change of course, leaving investors and market observers awaiting further clarification on the future of the resolution plan. The decision reverses the earlier announcement made on March 13, 2026, which had set the wheels in motion for the significant corporate action.

Background of the Restructuring Plan

The now-paused restructuring was a critical step following the approval of the company's BRP by the NCLT's Mumbai Bench on February 24, 2025. The plan was submitted by Resolution Applicant Ravindra Salunkhe, who is also the company's Managing Director. The core objective of the BRP was to recapitalize and reorganize the company after a period of significant financial and operational challenges. The restructuring intended for public shareholders involved a multi-step process, including a reduction of equity share capital, the subdivision of shares, and a fresh allotment of shares.

Key Components of the Withdrawn Plan

The corporate action was comprehensive and aimed at fundamentally altering the company's shareholding structure. Under the plan, public shareholders were to receive one new equity share for every thirteen existing shares they held. Additionally, the face value of equity shares held by the public was to be sub-divided from Rs. 10 per share to Rs. 1 per share. Any fractional entitlements resulting from the 1-for-13 share allotment were to be rounded off to the nearest whole number. This entire process was contingent on the record date, which has now been retracted.

Timeline of Corporate Actions

To understand the context of this withdrawal, it is important to review the sequence of events that led to this point. The process began over a year ago with the NCLT's intervention, setting a clear path for the company's resolution. The recent withdrawal disrupts this established timeline.

• February 24, 2025: The NCLT Mumbai Bench approves the Base Resolution Plan submitted by Ravindra Salunkhe.
• March 13, 2026: Garodia Chemicals announces March 25, 2026, as the record date for the share capital reduction and subdivision.
• March 25, 2026: The intended record date for determining eligible shareholders for the restructuring.
• April 02, 2026: The company formally intimates the BSE about the complete withdrawal of the record date.

Market and Shareholder Impact

The withdrawal of the record date introduces a significant element of uncertainty for the company's public shareholders. Investors who had made decisions based on the upcoming restructuring are now left without a clear timeline. The BRP was seen as a crucial step toward reviving the company, which has previously faced challenges including heavy losses and halts in manufacturing operations. The delay or potential cancellation of this key part of the plan could impact investor confidence and delay the company's path to operational and financial stability. The lack of a stated reason for the withdrawal further complicates the situation, making it difficult for stakeholders to assess the company's next steps.

What Lies Ahead?

With the record date withdrawn, the implementation of the NCLT-approved resolution plan is effectively on hold. The immediate focus will be on any forthcoming communication from Garodia Chemicals' management. Shareholders and the market will be looking for an official statement explaining the rationale behind the withdrawal and providing a revised timeline or an alternative course of action. The company is still bound by the NCLT's order, and any significant deviation from the approved BRP would likely require further regulatory or judicial approvals. The future of the company's restructuring now depends on the management's next disclosure to the exchanges.